|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||0.0900 - 0.1192|
|52-week range||0.0900 - 0.1192|
|Beta (5Y monthly)||1.29|
|PE ratio (TTM)||N/A|
|Earnings date||14 Mar 2022 - 18 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Tonix Pharmaceuticals (NASDAQ: TNXP) is a biotech stock that's having an absolutely awful week. On Wednesday, the company's shares fell sharply for a third straight day, closing more than 13% lower. Investors are clearly shaken by Tonix's current attempt at financial engineering.
Shares of Tonix Pharmaceuticals Holding (NASDAQ: TNXP) were crashing 22.7% as of 10:54 a.m. ET on Tuesday. This stock split took effect today. Reverse stock splits aren't a sign that things are going well for a company.
All stocks have bad days at least once in a while, but Monday for Tonix Pharmaceuticals (NASDAQ: TNXP) was one of the ugliest trading sessions in its history. The company's stock lost nearly one-third of its value after the company announced a financial engineering move that sent investors scrambling for the exits. Tonix announced Monday afternoon that it is effecting a 1-for-32 reverse split of its common stock.